Halozyme (HALO) announced that Argenx’s (ARGX) Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Health, Labour and Welfare, or MHLW, for adults with chronic inflammatory demyelinating polyneuropathy. Vyvdura was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme reports FDA approval for Opdivo co-formulated with Enhanze
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy
- Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
- Halozyme withdraws proposal to acquire Evotec